ZA200209525B - Oral Pharmaceutical composition with controlled release and prolonged absorption. - Google Patents

Oral Pharmaceutical composition with controlled release and prolonged absorption. Download PDF

Info

Publication number: ZA200209525B
Authority: ZA; South Africa
Prior art keywords: composition; weight; proportion; external phase; individual
Prior art date: 2000-07-11

Application number

ZA200209525A

Other languages

English (en)

Inventor

Catherine Castan

Valerie Legrand

Remi Meyrueix

Gerard Soula

Original Assignee

Flamel Tech Sa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-11

Filing date

2002-11-22

Publication date

2003-11-24

2002-11-22 Application filed by Flamel Tech Sa filed Critical Flamel Tech Sa

2003-11-24 Publication of ZA200209525B publication Critical patent/ZA200209525B/en

Links

238000013270 controlled release Methods 0.000 title claims abstract description 14
230000002035 prolonged effect Effects 0.000 title claims abstract description 13
238000010521 absorption reaction Methods 0.000 title claims description 17
239000008203 oral pharmaceutical composition Substances 0.000 title claims description 4
239000000203 mixture Substances 0.000 claims abstract description 111
239000002245 particle Substances 0.000 claims abstract description 40
XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 claims abstract description 27
229960003105 metformin Drugs 0.000 claims abstract description 25
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims abstract description 17
229920000642 polymer Polymers 0.000 claims abstract description 17
239000004359 castor oil Substances 0.000 claims abstract description 16
235000019438 castor oil Nutrition 0.000 claims abstract description 16
ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims abstract description 16
239000000654 additive Substances 0.000 claims abstract description 15
239000011248 coating agent Substances 0.000 claims abstract description 15
238000000576 coating method Methods 0.000 claims abstract description 15
229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims abstract description 15
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 15
230000000996 additive effect Effects 0.000 claims abstract description 14
229920001477 hydrophilic polymer Polymers 0.000 claims abstract description 14
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims abstract description 12
239000000314 lubricant Substances 0.000 claims abstract description 12
239000007787 solid Substances 0.000 claims abstract description 11
239000001639 calcium acetate Substances 0.000 claims abstract description 10
229960005147 calcium acetate Drugs 0.000 claims abstract description 10
235000011092 calcium acetate Nutrition 0.000 claims abstract description 10
VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims abstract description 9
235000019359 magnesium stearate Nutrition 0.000 claims abstract description 9
239000001856 Ethyl cellulose Substances 0.000 claims abstract description 8
229920001249 ethyl cellulose Polymers 0.000 claims abstract description 8
235000019325 ethyl cellulose Nutrition 0.000 claims abstract description 8
239000011159 matrix material Substances 0.000 claims abstract description 8
239000003094 microcapsule Substances 0.000 claims abstract description 8
235000013855 polyvinylpyrrolidone Nutrition 0.000 claims abstract description 8
235000010443 alginic acid Nutrition 0.000 claims abstract description 7
229920000615 alginic acid Polymers 0.000 claims abstract description 7
230000007935 neutral effect Effects 0.000 claims abstract description 7
229920000036 polyvinylpyrrolidone Polymers 0.000 claims abstract description 7
FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims abstract description 6
229940072056 alginate Drugs 0.000 claims abstract description 6
239000002131 composite material Substances 0.000 claims abstract description 6
239000001267 polyvinylpyrrolidone Substances 0.000 claims abstract description 6
QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims abstract description 3
239000000546 pharmaceutical excipient Substances 0.000 claims description 27
210000001035 gastrointestinal tract Anatomy 0.000 claims description 19
-1 alkaline earth metal salts Chemical class 0.000 claims description 18
238000004090 dissolution Methods 0.000 claims description 18
239000007903 gelatin capsule Substances 0.000 claims description 18
239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 13
235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 13
UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 13
239000008199 coating composition Substances 0.000 claims description 11
150000001875 compounds Chemical class 0.000 claims description 10
229920002678 cellulose Polymers 0.000 claims description 9
235000010980 cellulose Nutrition 0.000 claims description 9
238000004132 cross linking Methods 0.000 claims description 9
239000000499 gel Substances 0.000 claims description 9
238000000338 in vitro Methods 0.000 claims description 9
238000012360 testing method Methods 0.000 claims description 9
239000001913 cellulose Substances 0.000 claims description 7
238000002360 preparation method Methods 0.000 claims description 7
239000004094 surface-active agent Substances 0.000 claims description 7
229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 6
239000001863 hydroxypropyl cellulose Substances 0.000 claims description 6
235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 6
239000004014 plasticizer Substances 0.000 claims description 6
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 5
239000011575 calcium Substances 0.000 claims description 5
229910052791 calcium Inorganic materials 0.000 claims description 5
239000003795 chemical substances by application Substances 0.000 claims description 5
239000013543 active substance Substances 0.000 claims description 4
239000003945 anionic surfactant Substances 0.000 claims description 4
235000005911 diet Nutrition 0.000 claims description 4
230000000378 dietary effect Effects 0.000 claims description 4
235000014113 dietary fatty acids Nutrition 0.000 claims description 4
238000007922 dissolution test Methods 0.000 claims description 4
239000000194 fatty acid Substances 0.000 claims description 4
229930195729 fatty acid Natural products 0.000 claims description 4
239000012530 fluid Substances 0.000 claims description 4
BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 claims description 4
BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims description 4
QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
229920002401 polyacrylamide Polymers 0.000 claims description 4
LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 claims description 4
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 claims description 4
XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical class [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 claims description 4
MHQJUHSHQGQVTM-HNENSFHCSA-N Octadecyl fumarate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)\C=C/C(O)=O MHQJUHSHQGQVTM-HNENSFHCSA-N 0.000 claims description 3
230000003178 anti-diabetic effect Effects 0.000 claims description 3
239000002736 nonionic surfactant Substances 0.000 claims description 3
229940071138 stearyl fumarate Drugs 0.000 claims description 3
JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical class OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 2
WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 2
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims description 2
OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 2
SGTNSNPWRIOYBX-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-{[2-(3,4-dimethoxyphenyl)ethyl](methyl)amino}-2-(propan-2-yl)pentanenitrile Chemical compound C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 SGTNSNPWRIOYBX-UHFFFAOYSA-N 0.000 claims description 2
LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 2
QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 2
229920000832 Cutin Polymers 0.000 claims description 2
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 2
ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 2
239000005642 Oleic acid Substances 0.000 claims description 2
BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims description 2
235000021355 Stearic acid Nutrition 0.000 claims description 2
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 2
NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 claims description 2
229910052783 alkali metal Inorganic materials 0.000 claims description 2
150000001340 alkali metals Chemical class 0.000 claims description 2
229910052784 alkaline earth metal Inorganic materials 0.000 claims description 2
229910052782 aluminium Inorganic materials 0.000 claims description 2
XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 claims description 2
229940063655 aluminum stearate Drugs 0.000 claims description 2
229940035676 analgesics Drugs 0.000 claims description 2
230000000954 anitussive effect Effects 0.000 claims description 2
239000000730 antalgic agent Substances 0.000 claims description 2
230000003288 anthiarrhythmic effect Effects 0.000 claims description 2
239000003242 anti bacterial agent Substances 0.000 claims description 2
230000003266 anti-allergic effect Effects 0.000 claims description 2
230000003257 anti-anginal effect Effects 0.000 claims description 2
230000003556 anti-epileptic effect Effects 0.000 claims description 2
230000001387 anti-histamine Effects 0.000 claims description 2
229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
239000002260 anti-inflammatory agent Substances 0.000 claims description 2
230000003110 anti-inflammatory effect Effects 0.000 claims description 2
230000002460 anti-migrenic effect Effects 0.000 claims description 2
230000000118 anti-neoplastic effect Effects 0.000 claims description 2
230000000648 anti-parkinson Effects 0.000 claims description 2
230000001407 anti-thrombic effect Effects 0.000 claims description 2
239000000043 antiallergic agent Substances 0.000 claims description 2
229940124345 antianginal agent Drugs 0.000 claims description 2
239000003416 antiarrhythmic agent Substances 0.000 claims description 2
229940088710 antibiotic agent Drugs 0.000 claims description 2
239000003146 anticoagulant agent Substances 0.000 claims description 2
229940127219 anticoagulant drug Drugs 0.000 claims description 2
239000001961 anticonvulsive agent Substances 0.000 claims description 2
239000000935 antidepressant agent Substances 0.000 claims description 2
229940005513 antidepressants Drugs 0.000 claims description 2
229960003965 antiepileptics Drugs 0.000 claims description 2
229940121375 antifungal agent Drugs 0.000 claims description 2
239000000739 antihistaminic agent Substances 0.000 claims description 2
229940125715 antihistaminic agent Drugs 0.000 claims description 2
229940030600 antihypertensive agent Drugs 0.000 claims description 2
239000002220 antihypertensive agent Substances 0.000 claims description 2
229940034982 antineoplastic agent Drugs 0.000 claims description 2
239000002246 antineoplastic agent Substances 0.000 claims description 2
239000000939 antiparkinson agent Substances 0.000 claims description 2
239000003434 antitussive agent Substances 0.000 claims description 2
229940124584 antitussives Drugs 0.000 claims description 2
239000003699 antiulcer agent Substances 0.000 claims description 2
239000003443 antiviral agent Substances 0.000 claims description 2
229940121357 antivirals Drugs 0.000 claims description 2
239000002249 anxiolytic agent Substances 0.000 claims description 2
230000000949 anxiolytic effect Effects 0.000 claims description 2
229940005530 anxiolytics Drugs 0.000 claims description 2
229960002274 atenolol Drugs 0.000 claims description 2
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 2
229960000830 captopril Drugs 0.000 claims description 2
229960001777 castor oil Drugs 0.000 claims description 2
150000001768 cations Chemical class 0.000 claims description 2
229920002301 cellulose acetate Polymers 0.000 claims description 2
229960000541 cetyl alcohol Drugs 0.000 claims description 2
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 claims description 2
150000001860 citric acid derivatives Chemical class 0.000 claims description 2
229940124558 contraceptive agent Drugs 0.000 claims description 2
239000003433 contraceptive agent Substances 0.000 claims description 2
238000005520 cutting process Methods 0.000 claims description 2
HSUGRBWQSSZJOP-RTWAWAEBSA-N diltiazem Chemical compound C1=CC(OC)=CC=C1[C@H]1[C@@H](OC(C)=O)C(=O)N(CCN(C)C)C2=CC=CC=C2S1 HSUGRBWQSSZJOP-RTWAWAEBSA-N 0.000 claims description 2
229960004166 diltiazem Drugs 0.000 claims description 2
150000002148 esters Chemical class 0.000 claims description 2
MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical group CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims description 2
150000004665 fatty acids Chemical class 0.000 claims description 2
230000035558 fertility Effects 0.000 claims description 2
150000002314 glycerols Chemical class 0.000 claims description 2
229940049654 glyceryl behenate Drugs 0.000 claims description 2
230000000055 hyoplipidemic effect Effects 0.000 claims description 2
239000003326 hypnotic agent Substances 0.000 claims description 2
230000000147 hypnotic effect Effects 0.000 claims description 2
239000000411 inducer Substances 0.000 claims description 2
239000003112 inhibitor Substances 0.000 claims description 2
QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 2
DKYWVDODHFEZIM-UHFFFAOYSA-N ketoprofen Chemical compound OC(=O)C(C)C1=CC=CC(C(=O)C=2C=CC=CC=2)=C1 DKYWVDODHFEZIM-UHFFFAOYSA-N 0.000 claims description 2
229960000991 ketoprofen Drugs 0.000 claims description 2
229910052749 magnesium Inorganic materials 0.000 claims description 2
239000011777 magnesium Substances 0.000 claims description 2
IUBSYMUCCVWXPE-UHFFFAOYSA-N metoprolol Chemical compound COCCC1=CC=C(OCC(O)CNC(C)C)C=C1 IUBSYMUCCVWXPE-UHFFFAOYSA-N 0.000 claims description 2
229960002237 metoprolol Drugs 0.000 claims description 2
229960005181 morphine Drugs 0.000 claims description 2
OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 2
ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 2
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 claims description 2
IPVQLZZIHOAWMC-QXKUPLGCSA-N perindopril Chemical compound C1CCC[C@H]2C[C@@H](C(O)=O)N(C(=O)[C@H](C)N[C@@H](CCC)C(=O)OCC)[C@H]21 IPVQLZZIHOAWMC-QXKUPLGCSA-N 0.000 claims description 2
229960002582 perindopril Drugs 0.000 claims description 2
125000005498 phthalate group Chemical class 0.000 claims description 2
229920001282 polysaccharide Polymers 0.000 claims description 2
239000005017 polysaccharide Substances 0.000 claims description 2
IENZQIKPVFGBNW-UHFFFAOYSA-N prazosin Chemical compound N=1C(N)=C2C=C(OC)C(OC)=CC2=NC=1N(CC1)CCN1C(=O)C1=CC=CO1 IENZQIKPVFGBNW-UHFFFAOYSA-N 0.000 claims description 2
229960001289 prazosin Drugs 0.000 claims description 2
239000003368 psychostimulant agent Substances 0.000 claims description 2
229960001404 quinidine Drugs 0.000 claims description 2
VMXUWOKSQNHOCA-LCYFTJDESA-N ranitidine Chemical compound [O-][N+](=O)/C=C(/NC)NCCSCC1=CC=C(CN(C)C)O1 VMXUWOKSQNHOCA-LCYFTJDESA-N 0.000 claims description 2
229960000620 ranitidine Drugs 0.000 claims description 2
229960002052 salbutamol Drugs 0.000 claims description 2
229960004889 salicylic acid Drugs 0.000 claims description 2
CXMXRPHRNRROMY-UHFFFAOYSA-N sebacic acid Chemical class OC(=O)CCCCCCCCC(O)=O CXMXRPHRNRROMY-UHFFFAOYSA-N 0.000 claims description 2
229940045902 sodium stearyl fumarate Drugs 0.000 claims description 2
239000008117 stearic acid Substances 0.000 claims description 2
229940124549 vasodilator Drugs 0.000 claims description 2
239000003071 vasodilator agent Substances 0.000 claims description 2
229960001722 verapamil Drugs 0.000 claims description 2
229960005069 calcium Drugs 0.000 claims 1
150000004676 glycans Chemical class 0.000 claims 1
229940091250 magnesium supplement Drugs 0.000 claims 1
229940057977 zinc stearate Drugs 0.000 claims 1
230000001225 therapeutic effect Effects 0.000 abstract description 5
238000009472 formulation Methods 0.000 abstract description 3
235000016709 nutrition Nutrition 0.000 abstract description 2
239000000969 carrier Substances 0.000 abstract 1
230000003111 delayed effect Effects 0.000 abstract 1
239000002552 dosage form Substances 0.000 description 12
230000002496 gastric effect Effects 0.000 description 11
239000008187 granular material Substances 0.000 description 8
239000000843 powder Substances 0.000 description 8
OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 7
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
239000011859 microparticle Substances 0.000 description 6
230000036470 plasma concentration Effects 0.000 description 6
229920003075 Plasdone™ K-29/32 polymer Polymers 0.000 description 5
239000000227 bioadhesive Substances 0.000 description 5
239000012729 immediate-release (IR) formulation Substances 0.000 description 5
238000000034 method Methods 0.000 description 5
210000000813 small intestine Anatomy 0.000 description 5
235000010413 sodium alginate Nutrition 0.000 description 5
239000000661 sodium alginate Substances 0.000 description 5
229940005550 sodium alginate Drugs 0.000 description 5
210000002784 stomach Anatomy 0.000 description 5
IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 4
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
230000008901 benefit Effects 0.000 description 4
229940071676 hydroxypropylcellulose Drugs 0.000 description 4
239000001768 carboxy methyl cellulose Substances 0.000 description 3
238000011161 development Methods 0.000 description 3
230000002209 hydrophobic effect Effects 0.000 description 3
230000003204 osmotic effect Effects 0.000 description 3
239000000047 product Substances 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
229920003091 Methocel™ Polymers 0.000 description 2
229920003096 Methocel™ K100M Polymers 0.000 description 2
PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
102000057297 Pepsin A Human genes 0.000 description 2
108090000284 Pepsin A Proteins 0.000 description 2
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
229920002125 Sokalan® Polymers 0.000 description 2
229920002472 Starch Polymers 0.000 description 2
229940124532 absorption promoter Drugs 0.000 description 2
239000003472 antidiabetic agent Substances 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
235000010948 carboxy methyl cellulose Nutrition 0.000 description 2
239000008112 carboxymethyl-cellulose Substances 0.000 description 2
229920001577 copolymer Polymers 0.000 description 2
235000015872 dietary supplement Nutrition 0.000 description 2
239000003814 drug Substances 0.000 description 2
230000000694 effects Effects 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
150000002191 fatty alcohols Chemical class 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
229940095884 glucophage Drugs 0.000 description 2
229920001600 hydrophobic polymer Polymers 0.000 description 2
230000000968 intestinal effect Effects 0.000 description 2
235000012054 meals Nutrition 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
229940111202 pepsin Drugs 0.000 description 2
210000001187 pylorus Anatomy 0.000 description 2
230000000717 retained effect Effects 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
239000008107 starch Substances 0.000 description 2
235000019698 starch Nutrition 0.000 description 2
230000008961 swelling Effects 0.000 description 2
239000001993 wax Substances 0.000 description 2
CONKBQPVFMXDOV-QHCPKHFHSA-N 6-[(5S)-5-[[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperazin-1-yl]methyl]-2-oxo-1,3-oxazolidin-3-yl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)N1CCN(CC1)C[C@H]1CN(C(O1)=O)C1=CC2=C(NC(O2)=O)C=C1 CONKBQPVFMXDOV-QHCPKHFHSA-N 0.000 description 1
RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
229920003134 Eudragit® polymer Polymers 0.000 description 1
229920002907 Guar gum Polymers 0.000 description 1
101000607872 Homo sapiens Ubiquitin carboxyl-terminal hydrolase 21 Proteins 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
102100039918 Ubiquitin carboxyl-terminal hydrolase 21 Human genes 0.000 description 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
229920006243 acrylic copolymer Polymers 0.000 description 1
239000000783 alginic acid Substances 0.000 description 1
229960001126 alginic acid Drugs 0.000 description 1
150000004781 alginic acids Chemical class 0.000 description 1
235000001014 amino acid Nutrition 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
230000002058 anti-hyperglycaemic effect Effects 0.000 description 1
239000003963 antioxidant agent Substances 0.000 description 1
235000006708 antioxidants Nutrition 0.000 description 1
238000013459 approach Methods 0.000 description 1
238000003556 assay Methods 0.000 description 1
229910052788 barium Inorganic materials 0.000 description 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 description 1
239000003833 bile salt Substances 0.000 description 1
230000035587 bioadhesion Effects 0.000 description 1
235000001465 calcium Nutrition 0.000 description 1
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
229910052802 copper Inorganic materials 0.000 description 1
239000010949 copper Substances 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
230000029087 digestion Effects 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000007888 film coating Substances 0.000 description 1
238000009501 film coating Methods 0.000 description 1
238000005188 flotation Methods 0.000 description 1
238000005243 fluidization Methods 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
230000030136 gastric emptying Effects 0.000 description 1
239000000665 guar gum Substances 0.000 description 1
235000010417 guar gum Nutrition 0.000 description 1
229960002154 guar gum Drugs 0.000 description 1
230000036571 hydration Effects 0.000 description 1
238000006703 hydration reaction Methods 0.000 description 1
239000008172 hydrogenated vegetable oil Substances 0.000 description 1
238000001727 in vivo Methods 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
239000008101 lactose Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
238000012423 maintenance Methods 0.000 description 1
150000002696 manganese Chemical class 0.000 description 1
238000004519 manufacturing process Methods 0.000 description 1
238000010907 mechanical stirring Methods 0.000 description 1
229960004329 metformin hydrochloride Drugs 0.000 description 1
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
210000004400 mucous membrane Anatomy 0.000 description 1
229910052759 nickel Inorganic materials 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
230000003000 nontoxic effect Effects 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
239000008194 pharmaceutical composition Substances 0.000 description 1
229940124531 pharmaceutical excipient Drugs 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
150000004804 polysaccharides Chemical class 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
238000012552 review Methods 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
238000005507 spraying Methods 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000003756 stirring Methods 0.000 description 1
229910052712 strontium Inorganic materials 0.000 description 1
CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 1
239000000454 talc Substances 0.000 description 1
229910052623 talc Inorganic materials 0.000 description 1
239000006068 taste-masking agent Substances 0.000 description 1
239000011573 trace mineral Substances 0.000 description 1
235000013619 trace mineral Nutrition 0.000 description 1
229960005486 vaccine Drugs 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
229920001285 xanthan gum Polymers 0.000 description 1
239000011701 zinc Substances 0.000 description 1
229910052725 zinc Inorganic materials 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
- A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Diabetes (AREA)
Emergency Medicine (AREA)
Endocrinology (AREA)
Hematology (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medical Preparation Storing Or Oral Administration Devices (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

ZA200209525A 2000-07-11 2002-11-22 Oral Pharmaceutical composition with controlled release and prolonged absorption. ZA200209525B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR0009047A FR2811571B1 (fr)	2000-07-11	2000-07-11	Composition pharmaceutique orale, permettant la liberation controlee et l'absorption prolongee d'un principe actif

Publications (1)

Publication Number	Publication Date
ZA200209525B true ZA200209525B (en)	2003-11-24

Family

ID=8852353

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200209525A ZA200209525B (en)	2000-07-11	2002-11-22	Oral Pharmaceutical composition with controlled release and prolonged absorption.

Country Status (13)

Country	Link
US (2)	US20040022849A1 (es)
EP (1)	EP1299090B1 (es)
JP (1)	JP2004502723A (es)
AT (1)	ATE319431T1 (es)
AU (1)	AU2001277570A1 (es)
BR (1)	BR0112532A (es)
CA (1)	CA2415378C (es)
DE (1)	DE60117801T2 (es)
ES (1)	ES2260253T3 (es)
FR (1)	FR2811571B1 (es)
IL (1)	IL153086A0 (es)
WO (1)	WO2002003964A1 (es)
ZA (1)	ZA200209525B (es)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2816840B1 (fr) *	2000-11-17	2004-04-09	Flamel Tech Sa	Medicament a base de microcapsules d'anti-hyperclycemiant a liberation prolongee et son procede de preparation
JP3834215B2 (ja)	2001-09-07	2006-10-18	アグリテクノ矢崎株式会社	ゲル被覆種子
FR2830447B1 (fr) *	2001-10-09	2004-04-16	Flamel Tech Sa	Forme galenique orale microparticulaire pour la liberation retardee et controlee de principes actifs pharmaceutiques
US8101209B2 (en)	2001-10-09	2012-01-24	Flamel Technologies	Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US7906145B2 (en)	2002-04-09	2011-03-15	Flamel Technologies	Oral pharmaceutical formulation in the form of aqueous suspension for modified release of active principle(s)
AU2003246791A1 (en)	2002-04-09	2003-10-20	Flamel Technologies	Oral suspension of amoxicillin capsules
US7670623B2 (en) *	2002-05-31	2010-03-02	Materials Modification, Inc.	Hemostatic composition
US8911781B2 (en)	2002-06-17	2014-12-16	Inventia Healthcare Private Limited	Process of manufacture of novel drug delivery system: multilayer tablet composition of thiazolidinedione and biguanides
US7985422B2 (en)	2002-08-05	2011-07-26	Torrent Pharmaceuticals Limited	Dosage form
US8216609B2 (en) *	2002-08-05	2012-07-10	Torrent Pharmaceuticals Limited	Modified release composition of highly soluble drugs
US8268352B2 (en) *	2002-08-05	2012-09-18	Torrent Pharmaceuticals Limited	Modified release composition for highly soluble drugs
US7560160B2 (en) *	2002-11-25	2009-07-14	Materials Modification, Inc.	Multifunctional particulate material, fluid, and composition
US20040265372A1 (en) *	2003-06-27	2004-12-30	David Wynn	Soft tablet containing high molecular weight cellulosics
US7448389B1 (en)	2003-10-10	2008-11-11	Materials Modification, Inc.	Method and kit for inducing hypoxia in tumors through the use of a magnetic fluid
WO2005065639A2 (en) *	2003-11-21	2005-07-21	Torrent Pharmaceuticals Limited	Novel pharmaceutical compositions
US20070219131A1 (en) *	2004-04-15	2007-09-20	Ben-Sasson Shmuel A	Compositions capable of facilitating penetration across a biological barrier
NZ550320A (en) *	2004-04-15	2010-02-26	Chiasma Inc	Compositions capable of facilitating penetration across a biological barrier
FR2889810A1 (fr) *	2005-05-24	2007-02-23	Flamel Technologies Sa	Forme medicamenteuse orale, microparticulaire, anti-mesurage
DE102005006539A1 (de) *	2005-02-11	2006-08-24	Merck Patent Gmbh	Biguanid enthaltende Zusammensetzungen
WO2006133733A1 (en)	2005-06-13	2006-12-21	Flamel Technologies	Oral dosage form comprising an antimisuse system
FR2891459B1 (fr) *	2005-09-30	2007-12-28	Flamel Technologies Sa	Microparticules a liberation modifiee d'au moins un principe actif et forme galenique orale en comprenant
US8652529B2 (en)	2005-11-10	2014-02-18	Flamel Technologies	Anti-misuse microparticulate oral pharmaceutical form
FR2892937B1 (fr) *	2005-11-10	2013-04-05	Flamel Tech Sa	Forme pharmaceutique orale microparticulaire anti-mesusage
US7811604B1 (en)	2005-11-14	2010-10-12	Barr Laboratories, Inc.	Non-effervescent, orally disintegrating solid pharmaceutical dosage forms comprising clozapine and methods of making and using the same
EP1993607A4 (en) *	2006-01-10	2012-03-28	Pipex Inc	PHARMACEUTICAL COMPOSITIONS AND METHODS FOR OBTAINING AND MAINTAINING A TARGETABLE, STABLE COPPER RATE AND PREVENTING AND TREATING CENTRAL NERVOUS SYSTEM DISEASES RELATED TO SERIAL COPPER RATE
US20070264346A1 (en) *	2006-02-16	2007-11-15	Flamel Technologies	Multimicroparticulate pharmaceutical forms for oral administration
US9023400B2 (en) *	2006-05-24	2015-05-05	Flamel Technologies	Prolonged-release multimicroparticulate oral pharmaceutical form
JP4741991B2 (ja)	2006-07-14	2011-08-10	株式会社日立製作所	シリアアライザ／デシリアライザ方式の転送装置
PL2343982T3 (pl)	2008-09-17	2017-10-31	Chiasma Inc	Kompozycje farmaceutyczne i związane z nimi sposoby dostarczania
WO2011090725A2 (en) *	2009-12-29	2011-07-28	Impax Laboratories, Inc.	Gastroretentive solid oral dosage forms with swellable hydrophilic polymer
CA3224506A1 (en)	2010-05-12	2011-11-17	Unicycive Therapeutics, Inc.	Lanthanum carbonate hydroxide, lanthanum oxycarbonate and methods of their manufacture and use
PL2872121T3 (pl)	2012-07-12	2019-02-28	SpecGx LLC	Kompozycje farmaceutyczne o przedłużonym uwalnianiu, zniechęcające do nadużywania
US10842802B2 (en)	2013-03-15	2020-11-24	Medicis Pharmaceutical Corporation	Controlled release pharmaceutical dosage forms
US9132096B1 (en)	2014-09-12	2015-09-15	Alkermes Pharma Ireland Limited	Abuse resistant pharmaceutical compositions
WO2016126830A1 (en)	2015-02-03	2016-08-11	Chiasma Inc.	Method of treating diseases
UY37341A (es)	2016-07-22	2017-11-30	Flamel Ireland Ltd	Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11504347B1 (en)	2016-07-22	2022-11-22	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en)	2016-07-22	2024-05-21	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en)	2016-07-22	2023-03-14	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en)	2016-07-22	2025-01-07	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en)	2016-07-22	2023-03-14	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
BR112021013766A2 (pt)	2019-03-01	2021-09-21	Flamel Ireland Limited	Composições de gama-hidroxibutirato com farmacocinética melhorada no estado alimentado
CN110354090B (zh) *	2019-07-29	2021-10-01	石药集团欧意药业有限公司	一种盐酸二甲双胍缓释片及其制备方法
CN111202718A (zh) *	2020-02-25	2020-05-29	北京鑫开元医药科技有限公司	一种盐酸雷尼替丁胶囊及其制备方法
US11141457B1 (en)	2020-12-28	2021-10-12	Amryt Endo, Inc.	Oral octreotide therapy and contraceptive methods
US11583510B1 (en)	2022-02-07	2023-02-21	Flamel Ireland Limited	Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US11779557B1 (en)	2022-02-07	2023-10-10	Flamel Ireland Limited	Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS6248618A (ja) *	1985-08-27	1987-03-03	Zeria Shinyaku Kogyo Kk	徐放性製剤およびその製造法
US5268182A (en) *	1988-06-24	1993-12-07	Abbott Laboratories	Sustained-release drug dosage units of terazosin
CA2007181C (en)	1989-01-06	1998-11-24	Angelo Mario Morella	Sustained release pharmaceutical composition
IT1250421B (it) *	1991-05-30	1995-04-07	Recordati Chem Pharm	Composizione farmaceutica a rilascio controllato con proprieta' bio-adesive.
FR2704146B1 (fr) *	1993-04-19	1995-07-13	Cripdom	Microcapsules d'acide acétylsalicylique à libération contrôlée.
AU680356B2 (en) *	1994-05-06	1997-07-24	Pfizer Inc.	Controlled-release dosage forms of azithromycin
DE4432757A1 (de)	1994-09-14	1996-03-21	Boehringer Mannheim Gmbh	Pharmazeutische Zubereitung enthaltend Metformin und Verfahren zu deren Herstellung
FR2725623A1 (fr) *	1994-10-18	1996-04-19	Flamel Tech Sa	Microcapsules medicamenteuses et/ou nutritionnelles pour administration per os
US5858398A (en) *	1994-11-03	1999-01-12	Isomed Inc.	Microparticular pharmaceutical compositions
AP1224A (en) *	1998-03-19	2003-11-14	Bristol Myers Squibb Co	Biphasic controlled release delivery system for high solubility pharmaceuticals and method.
US6099859A (en)	1998-03-20	2000-08-08	Andrx Pharmaceuticals, Inc.	Controlled release oral tablet having a unitary core
US5945123A (en) *	1998-04-02	1999-08-31	K-V Pharmaceutical Company	Maximizing effectiveness of substances used to improve health and well being
US6499158B1 (en) *	2000-10-30	2002-12-31	Steris, Inc.	Surgical table top and accessory clamp used thereon

2000
- 2000-07-11 FR FR0009047A patent/FR2811571B1/fr not_active Expired - Fee Related
2001
- 2001-07-10 CA CA2415378A patent/CA2415378C/fr not_active Expired - Fee Related
- 2001-07-10 AT AT01955397T patent/ATE319431T1/de not_active IP Right Cessation
- 2001-07-10 BR BR0112532-0A patent/BR0112532A/pt not_active IP Right Cessation
- 2001-07-10 EP EP01955397A patent/EP1299090B1/fr not_active Expired - Lifetime
- 2001-07-10 DE DE60117801T patent/DE60117801T2/de not_active Expired - Lifetime
- 2001-07-10 AU AU2001277570A patent/AU2001277570A1/en not_active Abandoned
- 2001-07-10 US US10/332,463 patent/US20040022849A1/en not_active Abandoned
- 2001-07-10 IL IL15308601A patent/IL153086A0/xx unknown
- 2001-07-10 JP JP2002508419A patent/JP2004502723A/ja active Pending
- 2001-07-10 WO PCT/FR2001/002224 patent/WO2002003964A1/fr active IP Right Grant
- 2001-07-10 ES ES01955397T patent/ES2260253T3/es not_active Expired - Lifetime
2002
- 2002-11-22 ZA ZA200209525A patent/ZA200209525B/en unknown
2007
- 2007-03-21 US US11/723,553 patent/US7879362B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
BR0112532A (pt)	2003-07-29
EP1299090B1 (fr)	2006-03-08
ATE319431T1 (de)	2006-03-15
DE60117801D1 (de)	2006-05-04
DE60117801T2 (de)	2006-11-23
ES2260253T3 (es)	2006-11-01
CA2415378C (fr)	2010-03-16
FR2811571A1 (fr)	2002-01-18
JP2004502723A (ja)	2004-01-29
FR2811571B1 (fr)	2002-10-11
EP1299090A1 (fr)	2003-04-09
IL153086A0 (en)	2003-06-24
US20040022849A1 (en)	2004-02-05
WO2002003964A1 (fr)	2002-01-17
CA2415378A1 (fr)	2002-01-17
US7879362B2 (en)	2011-02-01
AU2001277570A1 (en)	2002-01-21
US20070207214A1 (en)	2007-09-06

Publication	Publication Date	Title
US7879362B2 (en)	2011-02-01	Oral pharmaceutical compositions with controlled release and prolonged absorption
US10688058B2 (en)	2020-06-23	Muco-adhesive, controlled release formulations of levodopa and/or esters of levodopa and uses thereof
AU2003242818B2 (en)	2008-12-18	Compressed tablets comprising microcapsules with modified release
RU2385712C2 (ru)	2010-04-10	Рецептура с контролируемым высвобождением
EP0797435B1 (en)	2003-09-03	Controlled release matrix for pharmaceuticals
US9474721B2 (en)	2016-10-25	Abuse-resistant formulations
AU2001268722B2 (en)	2005-08-11	Rapidly expanding composition for gastric retention and controlled release of therapeutic agents, and dosage forms including the composition
AU2006297477B2 (en)	2011-02-10	Pharmaceutical dosage forms having immediate release and/or controlled release properties
US6805881B1 (en)	2004-10-19	Multiple unit controlled food effect-independent release pharmaceutical preparations and method for preparing the same
EP1555022A1 (en)	2005-07-20	Sustained release compound of acetamidophenol and tramadol
WO2007106960A9 (en)	2008-04-24	Controlled-release floating dosage forms
US20020119192A1 (en)	2002-08-29	Controlled release formulations for oral administration
WO2014028878A1 (en)	2014-02-20	Pharmaceutical compositions of memantine
JP2006507216A (ja)	2006-03-02	用量ダンピングの恐れを低減させた新規な薬物送達システムとしての徐放性固形製剤
KR20140121394A (ko)	2014-10-15	아캄프로세이트 제제, 그것의 사용 방법, 및 그것을 포함하는 조합
EP2386302A1 (en)	2011-11-16	A controlled release pharmaceutical dosage form of trimetazidine and processes for the preparation thereof
BG107055A (bg)	2003-06-30	Оралнa система с контролирано освобождаване на ципрофлоксацин за еднократно дневно приемане
WO1997025028A1 (en)	1997-07-17	Pharmaceutical controlled release beads comprising furosemide and a formulation containing said controlled release beads
CN101584683A (zh)	2009-11-25	美托拉宗缓释胶囊及其制备方法
Katakam et al.	2010	Floating drug delivery systems: a review
US10722458B2 (en)	2020-07-28	Amphipathic lipid-based sustained release compositions